Search alternatives:
significant teer » significant gender (Expand Search), significant trend (Expand Search), significant genes (Expand Search)
point decrease » point increase (Expand Search)
teer decrease » greater decrease (Expand Search)
Showing 1 - 20 results of 4,504 for search '(( significant teer decrease ) OR ( significant ((mean decrease) OR (point decrease)) ))', query time: 0.54s Refine Results
  1. 1
    Transepithelial resistance of NHBE decreases significantly after PAA exposure.

    Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

    Published 2025
    Save to List
    Saved in:
  2. 2
    BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells.

    BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

    Published 2024
    Save to List
    Saved in:
  3. 3
    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session.

    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.

    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

    Published 2024
    “…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns  =  not significant.…”
    Save to List
    Saved in:
  5. 5
    Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells.

    Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

    Published 2024
    Save to List
    Saved in:
  6. 6
    Middle cerebral artery mean flow velocity at three time points.

    Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 7
    PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity.

    PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

    Published 2025
    Save to List
    Saved in:
  8. 8
    The mean and standard deviation of parameters.

    The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 9
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: